by Laurent Rigal, Constance Alexandre-Dubroeucq, Renaud de Beaurepaire, Claire Le Jeunne, Philippe Jaury
Abstract:
Aims: The aim of the study was to assess the proportions of ‘high-risk’ drinkers’ abstinent or with ‘low-risk’ consumption levels 1 year after the initiation of high-dose baclofen. Methods: This is a retrospective ‘open’ study; the outcome of this study was to assess the level of alcohol consumption in the 12th month of treatment. Results: Of the 181 patients included, a follow-up evaluation was possible in 132 patients. The initial alcohol consumption of the 132 patients analysed averaged 182 ± 92 g/day. After 1 year, 80% of the 132 (i.e. 58% of 181) were either abstinent (n = 78) or drinking at low-risk levels (n = 28) in their 12th month of treatment. The mean baclofen dose at 1 year was 129 ± 71 mg/day. Conclusion: High-dose baclofen should be tested in randomized placebo-controlled trials among high-risk drinkers.
Reference:
Abstinence and ‘Low-Risk’ Consumption 1 Year after the Initiation of High-Dose Baclofen: A Retrospective Study among ‘High-Risk’ Drinkers (Laurent Rigal, Constance Alexandre-Dubroeucq, Renaud de Beaurepaire, Claire Le Jeunne, Philippe Jaury), In Alcohol and Alcoholism, volume 47, no. 4, 2012.AbstractAims: The aim of the study was to assess the proportions of ‘high-risk’ drinkers’ abstinent or with ‘low-risk’ consumption levels 1 year after the initiation of high-dose baclofen. Methods: This is a retrospective ‘open’ study; the outcome of this study was to assess the level of alcohol consumption in the 12th month of treatment. Results: Of the 181 patients included, a follow-up evaluation was possible in 132 patients. The initial alcohol consumption of the 132 patients analysed averaged 182 ± 92 g/day. After 1 year, 80% of the 132 (i.e. 58% of 181) were either abstinent (n = 78) or drinking at low-risk levels (n = 28) in their 12th month of treatment. The mean baclofen dose at 1 year was 129 ± 71 mg/day. Conclusion: High-dose baclofen should be tested in randomized placebo-controlled trials among high-risk drinkers.
Bibtex Entry:
@article{doi:10.1093/alcalc/ags028,
author = {Rigal, Laurent and Alexandre-Dubroeucq, Constance and de Beaurepaire, Renaud and Le Jeunne, Claire and Jaury, Philippe},
title = {Abstinence and ‘Low-Risk’ Consumption 1 Year after the Initiation of High-Dose Baclofen: A Retrospective Study among ‘High-Risk’ Drinkers},
journal = {Alcohol and Alcoholism},
volume = {47},
number = {4},
pages = {439},
year = {2012},
doi = {10.1093/alcalc/ags028},
URL = {http://dx.doi.org/10.1093/alcalc/ags028},
eprint = {https://academic.oup.com/oup/backfile/content_public/journal/alcalc/47/4/10.1093/alcalc/ags028/2/ags028.pdf}
,abstract = {<strong>Aims</strong>: The aim of the study was to assess the proportions of ‘high-risk’ drinkers’ abstinent or with ‘low-risk’ consumption levels 1 year after the initiation of high-dose baclofen. <strong>Methods</strong>: This is a retrospective ‘open’ study; the outcome of this study was to assess the level of alcohol consumption in the 12th month of treatment. <strong>Results</strong>: Of the 181 patients included, a follow-up evaluation was possible in 132 patients. The initial alcohol consumption of the 132 patients analysed averaged 182 ± 92 g/day. After 1 year, 80% of the 132 (i.e. 58% of 181) were either abstinent (n = 78) or drinking at low-risk levels (n = 28) in their 12th month of treatment. The mean baclofen dose at 1 year was 129 ± 71 mg/day. <strong>Conclusion</strong>: High-dose baclofen should be tested in randomized placebo-controlled trials among high-risk drinkers.},issn = 1464-3502}